RE:RE:For you AEZS shareholderGilles has no credibility by missing all targets he has set in the past on licensing deals (CoQ10 in H2 2023, functional drink by 2020) despite what he calls interested parties, advanced discussions and serious discussions for over a decade.
His record on clinical studies is even worse; Y-BG was to be fast tracked to a clinical study by 2020, 3 years later it has not even started with an excuse as to when they should do a toxicology study. The oat BG study was a failure as he did not read up on the latest research which was published before the study started which suggested the use of a satchet (solution) vs. a pill. The AV study had delays while he touted his genius thought of a combined phase 1/2a study which is commonly done, then he said a further delay due to the need to create a novel method to check AV in the urine, that was another 2 year delay in total.
He has no integrity; taking credit for 2022 record revenues by calling a routine contract renewal as a catalyst for 2022 record revenues which was in line with 10% growth, then finding out later that record revenue was due to a stocking campaign by their main customer, since then revenues have collapsed in 2023. In addition he gleefully accepted a Top 50 TSXV award (given in error) for 2022 performance which was based on share price appreciation at over 800% which did not occur, the share price was flat in 2022.
He couldn't run a simple business for over a decade at CZO where he generated no new customers or monetization of PGX. No company needs a CEO working remote with a laisse- faire attitude.